ClinConnect ClinConnect Logo
Search / Trial NCT05965115

The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study

Launched by SHANGHAI ZHONGSHAN HOSPITAL · Jul 20, 2023

Trial Information

Current as of July 26, 2025

Recruiting

Keywords

Monoclonal Gammopathy Of Undetermined Significance Multiple Myeloma Early Tumor Screening

ClinConnect Summary

The CHAPERONE study is looking at how screening for a specific protein called M-protein can help identify early signs of a condition called monoclonal gammopathy in people who are closely related to patients with multiple myeloma, a type of blood cancer. This study aims to understand if screening can help find individuals who may be at risk of developing multiple myeloma in the future. By gathering information from these first-degree relatives, including parents, children, and siblings, researchers hope to learn more about what factors might lead to the progression of this disease.

To be eligible for the study, participants need to be at least 18 years old and have a close family member with a diagnosed case of multiple myeloma. It's important that participants understand the purpose of the study and agree to take part in the screening process. Those who are already diagnosed with related conditions like monoclonal gammopathy or multiple myeloma cannot participate. As a participant, you can expect to undergo screening tests and follow-up as part of the study, helping contribute valuable information that could improve understanding and treatment of this condition in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Male or female over the age of 18;
  • 2. First-degree relatives (including parents, children, and biological siblings) have multiple myeloma diagnosed by the International Myeloma Working Group (IMWG) Myeloma Diagnostic Criteria;
  • 3. Understand the purpose and procedure of this trial and voluntarily participate in this screening study;
  • 4. Participants should be willing and able to follow the study follow-up plan and other protocol requirements.
  • Exclusion Criteria:
  • Patients with a known diagnosis of plasma cell diseases, such as MGUS, smoldering myeloma (SMM), or multiple myeloma

About Shanghai Zhongshan Hospital

Shanghai Zhongshan Hospital is a prestigious medical institution affiliated with Fudan University, renowned for its commitment to advancing healthcare through rigorous clinical research and innovative patient care. With a focus on multidisciplinary collaboration and cutting-edge medical technologies, the hospital conducts a wide range of clinical trials aimed at improving treatment outcomes across various specialties. Its state-of-the-art facilities and highly qualified research team ensure that trials adhere to the highest ethical and scientific standards, contributing significantly to the global body of medical knowledge and enhancing patient health outcomes.

Locations

Shanghai, Shanghai, China

Patients applied

0 patients applied

Trial Officials

Peng Liu, PhD, MD

Principal Investigator

Fudan University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported